FDA Grants Final Approval for BMS' Opdivo and Yervoy Combination Therapy as First-Line Treatment for MSI-H/dMMR Colorectal Cancer
1. A New Milestone in First-Line Colorectal Cancer Treatment
The FDA has granted final approval for the combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) from Bristol Myers Squibb (BMS) for the first-line treatment of metastatic colorectal cancer with MSI-H (high microsatellite instability) and dMMR (mismatch repair deficient). This approval marks a significant turning point, shifting the focus of early colorectal cancer treatment from conventional chemotherapy to immuno-oncology. In addition, Opdivo monotherapy, which previously had accelerated approval, has now received regular approval, further strengthening BMS's portfolio of immune checkpoint inhibitors.
2. Overwhelming Efficacy Proven in the CheckMate-8HW Trial
The pivotal Phase 3 CheckMate-8HW trial, which served as the basis for this regulatory approval, was the largest immuno-oncology trial conducted for this indication. The trial results demonstrated that the combination therapy of Opdivo and Yervoy reduced the risk of disease progression and death by an impressive 79% compared to standard chemotherapy. While the median progression-free survival (PFS) in the control group was 5.8 months, the combination therapy group achieved a median that was not reached, demonstrating the potential for long-term survival. The objective response rate (ORR) was also 69%, nearly double the 37% observed with conventional chemotherapy.
3. Fierce Competition with Keytruda's Dominant Market Position
With this approval, BMS will now directly compete with Merck's Keytruda (pembrolizumab) in the first-line treatment market for MSI-H/dMMR colorectal cancer, which Keytruda has dominated. Keytruda achieved a median PFS of 16.5 months in the KEYNOTE-177 trial, establishing its market presence. However, the combination therapy of Opdivo and Yervoy offers a compelling alternative to physicians and patients with a unique 79% risk reduction.
4. Enhanced Patient Convenience and Long-Term Revenue Diversification
In addition to this combination therapy approval, BMS has recently approved Opdivo Qvantig, a subcutaneous formulation of Opdivo, to improve the convenience of intravenous administration. Entering the first-line treatment market not only significantly extends patients' survival but also extends the duration of drug administration, maximizing revenue contribution per prescription. As patent expiration approaches, expanding indications and innovating formulations are expected to play a key role in defending drug prices and attracting new patients.
This approval represents a critical commercial milestone for BMS, as its blockbuster drug, Opdivo, with annual sales of $10 billion, makes a full-fledged entry into the first-line colorectal cancer market, directly challenging the market dominance of Merck's Keytruda. The impressive data from the Phase 3 CheckMate-8HW trial, which demonstrated a 79% reduction in the risk of disease progression and death compared to chemotherapy, suggests that dual immune checkpoint inhibition therapy has the potential to reshape the standard of care in the solid tumor market. In the short term, this will lead to immediate revenue growth through increased prescriptions, and in the medium to long term, it will provide strong momentum for the subcutaneous formulation strategy and indication diversification to prepare for patent expiration. Furthermore, it provides valuable clinical data and research insights for the industry and researchers on overcoming the limitations of single-agent immunotherapy through dual checkpoint inhibition.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=BLA125554